| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Research Abstract |
Here, I and my colleagues performed a series of optical imaging experiments to visualize intratumoral HIF-1 activity, and optimized some combination of radiation with antitumor drugs, which could modulate HIF-1 activity, such as a VEGF neutralizing agent, bevacizumab, and a HIF-1 inhibitor, YC-1.
1. Optical imaging experiments showed that administration of a VEGF-neutralizing agent, bevacizumab, temporally induced vascular normalization and decreased hypoxic fraction in tumor xenografts 1 day after the treatment. When radiation treatment was given in this timing, the combined treatment significantly delayed tumor growth compared to radiation therapy alone.
2. We found that administration of a HIF-1 inhibitor, YC-1, suppressed radiation-induced activation of intratumoral HIF-1 activity, and then significantly delayed the growth of recurrent tumor after radiation therapy.
|
